Compare BLBD & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLBD | TNDM |
|---|---|---|
| Founded | 1927 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | N/A | 2013 |
| Metric | BLBD | TNDM |
|---|---|---|
| Price | $47.85 | $22.58 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 16 |
| Target Price | ★ $64.60 | $24.00 |
| AVG Volume (30 Days) | 370.9K | ★ 1.4M |
| Earning Date | 02-04-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.79 | N/A |
| EPS | ★ 3.88 | N/A |
| Revenue | ★ $1,480,099,000.00 | $1,007,001,000.00 |
| Revenue This Year | $4.86 | $8.59 |
| Revenue Next Year | $3.41 | $10.19 |
| P/E Ratio | $12.13 | ★ N/A |
| Revenue Growth | 9.87 | ★ 17.87 |
| 52 Week Low | $30.04 | $9.98 |
| 52 Week High | $61.95 | $38.18 |
| Indicator | BLBD | TNDM |
|---|---|---|
| Relative Strength Index (RSI) | 39.98 | 57.11 |
| Support Level | $46.44 | $21.35 |
| Resistance Level | $47.89 | $23.95 |
| Average True Range (ATR) | 1.34 | 0.91 |
| MACD | -0.29 | -0.13 |
| Stochastic Oscillator | 25.33 | 45.39 |
Blue Bird Corp is an American bus manufacturing company. It is an independent designer and manufacturer of school buses. The company operates in two segments; the Bus segment which involves the design, engineering, manufacture, and sales of school buses and extended warranties; and the Parts segment which includes the sales of replacement bus parts. Geographically, the company generates a majority of its revenue from its customers in the United States and the rest from Canada and Rest of the world.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.